Simultaneous determination of HIV-protease inhibitors lamivudine and zidovudine in pharmaceutical formulations by micellar electrokinetic chromatography
Authors:
- 1 September 2005
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 39 (3-4) , 653-660
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effect of antiviral treatment on the shedding of HIV-1 in semenAIDS, 1997
- Effects of Reverse Transcriptase Inhibitor Therapy on the HIV-1 Viral Burden in SemenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group1996
- (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroAntimicrobial Agents and Chemotherapy, 1992
- Clinical Pharmacology of 3'-Azido-2',3'-Dideoxythymidine (Zidovudine) and Related DideoxynucleosidesNew England Journal of Medicine, 1989
- Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Simple and rapid high-performance liquid chromatographic assay for zidovudine (azidothymidine) in plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitroAntimicrobial Agents and Chemotherapy, 1986
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences, 1986
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences of the United States of America, 1985